

Humber Area Prescribing Committee

Date / Time	3 rd November 2022 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Andrew Karvot – Advanced Clinical and Northern Lincolnshire - Interface Pharmacist (AK) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Simon Priestley- Chief Pharmacist, NLAG (SP) Prof A Morice – Professor of Respiratory Medicine, Chair of D&TC HUTH (AM) Joanne Goode – Chief Pharmacist – HUTH (JG) Daniel Newsome- Principal Pharmacist RDTC (DN) Dr Anupam Sinha- NEL GP Prescribing Lead (AS) Alberto Ortiz-Moya – Interim Principal Pharmacist MH & LD Services
-------------------	---

Apologies	Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist) , CHCP (EB) Luke Storr – Senior Pharmacy Technician, HUTH Dr Rolan Schreiber, Professional Secretary LMC (RSx) Dr Narayana Pothina- Consultant in adult medicine – NLAG (NP)
------------------	--

Agenda Number	Item	Discussion	Action	Lead	Due Date
2022.11.01	Apologies	Noted above			
		Not quorate and thus discussion regarding a backup plan for when certain roles are needed/given apologies to ensure meeting is viable and can action points. JM to send approved documents to Dr Pothina to confirm he is happy with.			
2022.11.02	Declarations of interest	None			
2022.11.03	Minutes of previous meeting	Accepted as true record			
2022.11.04	Action Tracker	<ul style="list-style-type: none"> • Outstanding actions from NLAPC Overactive bladder pathway – JM to contact Mr Gandhi with pathway for agreement in HUTH and to contact ICP team to see if discussed there. • Joint formulary Transfer chapter 4 onto netformulary site Action ongoing- 90% complete • Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) • Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred October update – JM to contact Matthew Heppel for timeframes for updated guidance • Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF • Action tracker NLAPC – Triptorelin 	<p>JM to keep chasing MR Ghandi</p> <p>Ongoing</p> <p>Ongoing- New document to be created</p> <p>Ongoing- JM to discuss with Matthew on timeline</p> <p>Ongoing</p>	<p>JM</p> <p>JM/AK</p> <p>AK/JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM/AK</p>	<p>8/22</p> <p>11/22</p> <p>3/23</p> <p>11/22</p> <p>3/23</p> <p>3/23</p>

		<p>JM/AK to share HERPC guideline with Mr Rogers for transfer into a joint document</p> <ul style="list-style-type: none"> • Traffic light status: Update formulary and red lists • Ratification of guidelines and SCFs To upload guidelines and dementia SCF to website and remove relevant HERPC guidance/SCF • Ratification of joint formulary To upload chapter 2 onto joint formulary and remove HERPC chapter 2 when live • RTDC updates JM to contact Dr Narayanan for application for isosepent ethyl (TA805) and updated triglycerides pathway • AOB To add classification for oral posiconazole to NLAPC formulary chapter 5.- Added to NLAPC formulary • AOB KMc to confirm with relevant finance team in Hull that previous agreement for patient on sodium oxybate transferring to adult services remains. 	<p>Ongoing- JM to send to AK</p> <p>Action Complete</p> <p>Action Complete</p> <p>JM to double check and add links then complete</p> <p>TA805 To be discussed at HUTH D&T. Pathway updated</p> <p>Action Complete</p> <p>Action Complete</p>	<p>LS/AK</p> <p>JM/AK</p> <p>JM/LS/AK</p> <p>JM</p> <p>AK</p> <p>KMc</p>	<p>11/22</p> <p>11/22</p> <p>1/23</p> <p>11/23</p> <p>11/23</p> <p>11/23</p>
2022.11.05	Outstanding actions from NLAPC	<ul style="list-style-type: none"> • Mycophenolate- Awaiting funding • <i>Modafinil</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • <i>Azathioprine/6MP shared care for gastro</i>- Shared cared accepted, awaiting clarification around funding. • <i>Riluzole shared care</i>- Shared care approved, awaiting confirmation of funding in both NEL/NL as want to launch when funding available at both Places • ADHD Shared care (NL) – awaiting confirmation of funding- Going to mental health meeting update next meeting- RS not had feedback as of yet, will follow up • <i>Prescribing in gestational diabetes</i>- Discussed at business meeting and currently being looked at standardisation of practice across Northern Lincolnshire places- update next meeting • <i>Appropriate prescribing of specialist infant formulae</i>- AK has emailed a community dietitian to ask if they are happy to review and work with north bank on this- 	<p>Ongoing- data gathering on numbers of PTs</p> <p>Ongoing- data gathering on numbers of PTs</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>		

		AK not received back, update next meeting- No update AK to chase			
2022.11.06	Outstanding actions from HERPC	<ul style="list-style-type: none"> • Correspondence Received Rheumatology to prepare pathway with rituximab without MTX No contact from Dr Ogumbambi, JM spoke to director, meeting to be set up. • Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline JM updated document and sent to Gary Hepworth- document circulated • Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. New action for HAPC To prepare SCF • Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team- JM no correspondence from Mrs Allen, reply from specialist nurse. JM to contact Mrs Allen again • Prescribing guidelines – Renal transplant medicines JM to update with alternative H2 receptor antagonist and review plan for renal repatriation. JM contacted lead renal consultant to discuss to move to HAPC tracker. 	Ongoing Ongoing Ongoing New action for HAPC tracker: JM to prepare SCF Ongoing Ongoing	JM JM JM	
2022.11.07	Traffic Light Status	October 22- HUTH D&T Pembrolizumab- Proposed as RED MISC- Octreotide SC immediate acting- proposed -AMBER 1	Update formulary/red list	LS/AK	11/22
2022.11.08	Feedback from Integrated Medicines Optimisation Committee	Discussion of NICE process within acute trusts, which was raised due TA805 discussion with HUTH. To be discussed at agenda point Sodium valproate- barriers of implementation consultation sent across ICB	Noted		
2022.11.09	Work plans	<ol style="list-style-type: none"> a) Joint formulary alignment b) Shared care frameworks c) Guidelines 	Ongoing for information only		

2022.11.10	Ratification of guidelines and SCFs	Nil this month			
2022.11.11	Ratification of joint formulary	Chapter 13- Discussion on minocycline for treatment of acne- set as RED. RS raised point that minocycline is RED and BLACK in other areas. Add in Doxycycline for treatment of acne- GREEN Minocycline for treatment of rosacea classified as RED Discussion of preparations for genital warts and classified as RED 13.8-Sunscreen and Camouflages- JM suggested to raise to IMOC as difference in commissioning on a few items. Sunsense- AMBER 1- ACBS only Eflomithrine- RED- look at usage Look at usage of camouflages Aluminium Chloride- suggest OTC			
2022.11.12	RTDC updates	September 22- JM provided an update to NICE.			
2022.11.13	NICE TA process	Discussed in RDTC update. Discussed if should change way of new TA should have another application if item is already on formulary	Verbal discussion		
2022.11.14	Minutes from subcommittees	a) Joint formulary subcommittee (August 22) b) Guideline subcommittee (July 22)	Attached for info only		
2022.11.15	Additional minutes for information	a) HUTH D&TC (Sep 2022) b) HFT DTG (nil this month) c) NLAG M&T (Nil this month) d) NYY APC (Sep 2022)	Attached for info only		
2022.11.16	AOB	<ul style="list-style-type: none"> AK raised a concern that oral vancomycin had been placed on a discharge but full course was not supplied and GP requested to supply RS raise a point that if APCs should consider devices in relation to medicines such as constant glucose monitoring. Agreed that should be discussed at APC and prescribable devices are part of TOR. RS ICB clinical review group looking into gluten free products JM raised a prescription query on Forceval as not classified on South Bank. 			
2022.11.17	Date of next meeting	7 th December 13.00 – 15.00 Teams			